Preclinical studies of Bintrafusp alfa revealed that the anti-PD-L1/TGFβ Trap fusion protein, not the anti-PD-L1 antibody, reversed the mesenchymalization of cancer cells, thereby sensitizing tumor cells to chemotherapy (NCT03631706). The gene discussed is CD274; the disease is neoplasm.